Clinical

ADaM: The Unsung Hero of Clinical Trial Data Analysis
  1. Clinical

ADaM: The Unsung Hero of Clinical Trial Data Analysis

IntroductionImagine you’re a researcher working on a groundbreaking clinical trial. You’ve collected mountains of data, but now comes the hard part—making sense of it all. Enter ADaM, the Analysis Data Model developed by CDISC. ADaM is the unsung hero that transforms raw data into actionable insights, ensuring your trial meets regulatory standards and delivers reliable […]
Written by
  1. Clinical

Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer

CRANBURY, N.J.–(BUSINESS WIRE) Aug 14, 2024 –Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced today that the US Food and Drug Administration (FDA) has granted the investigation of AC699 a Fast Track designation for the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, estrogen […]
Written by
  1. Clinical

Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome

MELBOURNE, Australia, Aug. 14, 2024. Prota Therapeutics Pty Ltd (Prota), an Australian clinical-stage biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced publication in the journal Allergy of the first long-term study directly comparing remission and desensitization endpoints following food allergen oral immunotherapy (OIT). The Phase […]
Written by
  1. Clinical

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

LEXINGTON, Mass.–(BUSINESS WIRE)–Aug. 8, 2024– Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational […]
Written by
  1. Clinical

First Patients Enrolled in US Pivotal Study of AI-Based Image Analysis Module for Lung Cancer

SANTA CLARA, Calif., Aug. 9, 2024. Invenio Imaging, a leader in intraoperative fresh tissue imaging and artificial intelligence (AI), announced today the enrollment of the first patients in a US pivotal study of its AI-based image analysis module for lung cancer. The ON-SITE study, a multicenter study in bronchoscopy combining Stimulated Raman Histology with Artificial […]
Written by
  1. Clinical

WestGene to Advance Clinical Trials Following Dual IND Approvals for World’s First EB Virus-Related mRNA Therapeutic Cancer Vaccine

CHENGDU, China, Aug. 8, 2024. WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals from China’s National Medical Products Administration (NMPA) and the US FDA. This unprecedented achievement marks the world’s first IND-approved mRNA vaccine for EBV-related cancers in both the United States and China. On […]
Written by
  1. Clinical

Turn Therapeutics Topical Atopic Dermatitis Candidate Significantly Inhibits Key Cytokines in Expansion Study of Flagship Formula

WESTLAKE VILLAGE, Calif., Aug. 5, 2024. Turn Therapeutics, a pharmaceutical and medical device company focused on immunology, advanced wound care, and dermatology, announced today positive data results of GX-03 in a biomarker study intended to measure its immunological inhibitory effects during eczema induction. The study evaluated the immunological inhibitory effects of the topical application of […]
Written by
  1. Clinical

Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016

SAN FRANSCISO and SUZHOU, China, Aug. 1, 2024. Innovent Biologics, Inc. (“Innovent”), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and Sanegene Bio USA Inc. (SanegeneBio) today announced the first participant has been successfully dosed in a […]
Written by
  1. Clinical

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship […]
Written by
  1. Clinical

NIH Researchers Discover Potential Therapeutic Target for Degenerative Eye Disease

July 26, 2024 — Researchers from the National Institutes of Health (NIH) have discovered the source of dysfunction in the process whereby cells in the eye’s retina remove waste. A report by scientists at NIH and Johns Hopkins University, Baltimore, details how alterations in a factor called AKT2 affects the function of organelles called lysosomes […]
Written by

Good Reads

Sciendo Logo

Hematological and Biochemical Indices of a Local Rabbit…

Rabbit feed in Algeria is still based exclusively on commercial pelleted diets, but the recent use of non-conventional ingredients in feed formulation is becoming more frequent, and several studies were carried out on the incorporation of local raw materials in rabbit feed worldwide. However, studies related to the incorporation of Jujube are nonexistent. In this […]
Written by

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways

Arsenic effectively treats acute promyelocytic leukemia by inducing SUMO and ubiquitin-dependent degradation of the promyelocytic leukemia (PML)–retinoic acid receptor alpha oncogenic fusion protein. However, some patients relapse with arsenic-resistant disease because of missense mutations in PML. To determine the mechanistic basis for arsenic resistance, PML−/− cells were reconstituted with YFP fusions of wild-type PML-V and […]
Written by

Worlwide

Sciendo Logo

Hematological and Biochemical Indices of a Local Rabbit…

Rabbit feed in Algeria is still based exclusively on commercial pelleted diets, but the recent use of non-conventional ingredients in feed formulation is becoming more frequent, and several studies were carried out on the incorporation of local raw materials in rabbit feed worldwide. However, studies related to the incorporation of Jujube are nonexistent. In this […]
Written by

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways

Arsenic effectively treats acute promyelocytic leukemia by inducing SUMO and ubiquitin-dependent degradation of the promyelocytic leukemia (PML)–retinoic acid receptor alpha oncogenic fusion protein. However, some patients relapse with arsenic-resistant disease because of missense mutations in PML. To determine the mechanistic basis for arsenic resistance, PML−/− cells were reconstituted with YFP fusions of wild-type PML-V and […]
Written by

Why Climate Finance Is Key To Fighting Climate Change – State of the Planet

Flooding in Klodzku, Poland Photo: Jacek Halicki 2024 was the hottest year on record. Around the world, 151 unprecedented extreme weather events devastated countries around the planet, including heat waves in Japan and Iran, floods in Italy, Pakistan, Poland and Brazil, and typhoons in Vietnam and the Philippines. Massive sums of money are needed to […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.